Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H21NO3 |
Molecular Weight | 299.3642 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CC[C@@]23[C@H]4CCC(=O)[C@]2(C)OC5=C(O)C=CC(C[C@@H]14)=C35
InChI
InChIKey=NPZXCTIHHUUEEJ-CMKMFDCUSA-N
InChI=1S/C18H21NO3/c1-17-14(21)6-4-11-12-9-10-3-5-13(20)16(22-17)15(10)18(11,17)7-8-19(12)2/h3,5,11-12,20H,4,6-9H2,1-2H3/t11-,12+,17-,18-/m0/s1
Molecular Formula | C18H21NO3 |
Molecular Weight | 299.3642 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Metopon was developed as an analgesic opium derivative. This drug has a high affinity to the mu-opioid receptor and produces antinociception through this receptor. Metopon was available in Canada only in tablet form for oral administration; however, because of the drug addiction, the Drug Addiction Committee recommended its limited use.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18897557
Metopon will be available in Canada only in tablet form for oral administration. The tablets will be put up in bottles of 50 and each tablet will contain 8.0 mgm. of metopon hydrochloride.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:35:14 GMT 2025
by
admin
on
Mon Mar 31 17:35:14 GMT 2025
|
Record UNII |
94XZ1CC69D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Mon Mar 31 17:35:14 GMT 2025 , Edited by admin on Mon Mar 31 17:35:14 GMT 2025
|
||
|
DEA NO. |
9260
Created by
admin on Mon Mar 31 17:35:14 GMT 2025 , Edited by admin on Mon Mar 31 17:35:14 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000080922
Created by
admin on Mon Mar 31 17:35:14 GMT 2025 , Edited by admin on Mon Mar 31 17:35:14 GMT 2025
|
PRIMARY | |||
|
METOPON
Created by
admin on Mon Mar 31 17:35:14 GMT 2025 , Edited by admin on Mon Mar 31 17:35:14 GMT 2025
|
PRIMARY | |||
|
C83963
Created by
admin on Mon Mar 31 17:35:14 GMT 2025 , Edited by admin on Mon Mar 31 17:35:14 GMT 2025
|
PRIMARY | |||
|
m7497
Created by
admin on Mon Mar 31 17:35:14 GMT 2025 , Edited by admin on Mon Mar 31 17:35:14 GMT 2025
|
PRIMARY | Merck Index | ||
|
1785
Created by
admin on Mon Mar 31 17:35:14 GMT 2025 , Edited by admin on Mon Mar 31 17:35:14 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110992
Created by
admin on Mon Mar 31 17:35:14 GMT 2025 , Edited by admin on Mon Mar 31 17:35:14 GMT 2025
|
PRIMARY | |||
|
5359353
Created by
admin on Mon Mar 31 17:35:14 GMT 2025 , Edited by admin on Mon Mar 31 17:35:14 GMT 2025
|
PRIMARY | |||
|
4189
Created by
admin on Mon Mar 31 17:35:14 GMT 2025 , Edited by admin on Mon Mar 31 17:35:14 GMT 2025
|
PRIMARY | |||
|
DTXSID20162275
Created by
admin on Mon Mar 31 17:35:14 GMT 2025 , Edited by admin on Mon Mar 31 17:35:14 GMT 2025
|
PRIMARY | |||
|
143-52-2
Created by
admin on Mon Mar 31 17:35:14 GMT 2025 , Edited by admin on Mon Mar 31 17:35:14 GMT 2025
|
PRIMARY | |||
|
C046877
Created by
admin on Mon Mar 31 17:35:14 GMT 2025 , Edited by admin on Mon Mar 31 17:35:14 GMT 2025
|
PRIMARY | |||
|
94XZ1CC69D
Created by
admin on Mon Mar 31 17:35:14 GMT 2025 , Edited by admin on Mon Mar 31 17:35:14 GMT 2025
|
PRIMARY | |||
|
SUB08909MIG
Created by
admin on Mon Mar 31 17:35:14 GMT 2025 , Edited by admin on Mon Mar 31 17:35:14 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |